Plasminogen Activator Inhitor-1 Associates with Cardiovascular Risk Factors in Healthy Young Adults in the Cardiovascular Risk in Young Finns Study
Overview
Authors
Affiliations
Aims: Hypofibrinolysis displayed by elevated serum plasminogen activator inhibitor 1 (PAI-1) level has been associated with cardiovascular disease (CVD) and its risk factors such as obesity and insulin resistance. However, no studies have examined associations between PAI-1 and CVD risk factors in healthy subjects. We examined associations between serum PAI-1, ultrasound markers of atherosclerosis and CVD risk factors and whether PAI-1 improves prediction of atherosclerosis over known risk factors in a cohort of asymptomatic adults.
Methods: We analyzed PAI-1 and CVD risk factors and assessed carotid intima-media thickness (cIMT), distensibility (CDist) and the presence of a carotid atherosclerotic plaque and flow-mediated dilation (FMD) ultrasonographically for 2202 adults (993 men and 1,209 women, aged 30-45 years) participating in the ongoing longitudinal cohort study, The Cardiovascular Risk in Young Finns Study. High cIMT was defined as >90th percentile and/or carotid plaque and low CDist and low FMD as <20th percentile.
Results: In bivariate analyses, PAI-1 correlated directly with cIMT and the risk factors: blood pressure, BMI, waist and hip circumference, alcohol use, total and LDL-cholesterol, triglycerides, glomerular filtration rate, high-sensitivity CRP and glucose (all P<0.005). PAI-1 was higher in men and increased with age. Inverse correlation was observed with CDist, HDL-cholesterol and adiponectin in both sexes, with testosterone and sex hormone binding globulin in men and with creatinine and oral contraceptive use in women (P<0.005). Independent direct associations were observed between PAI-1 and waist circumference, serum triglycerides, insulin, alcohol use and age and inverse with serum creatinine, HDL-cholesterol and adiponectin. PAI-1 did not improve estimation of high cIMT, low CDist and low FMD over conventional risk factors (P for difference in area under curve ≥ 0.37).
Conclusion: PAI-1 was independently associated with several known CVD risk factors, especially obesity markers, in both men and women. However, addition of PAI-1 to known risk factors did not improve cross-sectional prediction of high cIMT, low CDist and low FMD suggesting that PAI-1 is not a clinically important biomarker in early atherosclerosis.
Kusters C, Paul K, Lu A, Ferruci L, Ritz B, Binder A Geroscience. 2023; 46(1):1053-1069.
PMID: 37369886 PMC: 10828310. DOI: 10.1007/s11357-023-00832-3.
Crucial Regulatory Role of Organokines in Relation to Metabolic Changes in Non-Diabetic Obesity.
Lorincz H, Somodi S, Ratku B, Harangi M, Paragh G Metabolites. 2023; 13(2).
PMID: 36837889 PMC: 9967669. DOI: 10.3390/metabo13020270.
Leukocyte metabolism in obese type 2 diabetic individuals associated with COVID-19 severity.
Lobato T, Gennari-Felipe M, Pauferro J, Correa I, Santos B, Dias B Front Microbiol. 2022; 13:1037469.
PMID: 36406408 PMC: 9670542. DOI: 10.3389/fmicb.2022.1037469.
Basu A, Izuora K, Betts N, Kinney J, Salazar A, Ebersole J Nutrients. 2021; 13(5.
PMID: 33922576 PMC: 8145532. DOI: 10.3390/nu13051421.
Pasquarelli-do-Nascimento G, Braz-de-Melo H, Faria S, de Oliveira Santos I, Kobinger G, Magalhaes K Front Endocrinol (Lausanne). 2020; 11:530.
PMID: 32849309 PMC: 7399077. DOI: 10.3389/fendo.2020.00530.